Citius Pharmaceuticals, Inc.
CTXRHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCitius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. With a market capitalization of $11.1M, it sits in micro-cap territory. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Market Cap
$11.1M
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-0.28
EPS (TTM)
$-1.75
EPS (Fwd)
$-1.44
ROE
-81.1%
ROA
-26.6%
Cash
$17.0M
Total Debt
$7.2M
Free CF
-$36.8M
52W Change
-77.9%
Annual Financials
Cash vs Debt
Where CTXR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CTXR finished 31.75% below its 150-day moving average ($0.63) and 36.76% below its 200-day moving average ($0.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTXR overbought or oversold?
At the October 20, 2026 close, CTXR's RSI(14) was 19.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Citius Pharmaceuticals, Inc. holds $17.0M in cash against $7.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$36.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -81.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Citius Pharmaceuticals, Inc. and its sector.